// App-Quantinova.ai

Su1391 : Infliximab Therapy in Pediatric Crohn's Disease: Results From Develop, a Multicenter Prospective Inflammatory Bowel Disease Registry

Researchers

Presenter

  • Salvatore Cucchiara

Principal Investigators

  • Harland Winter

  • Richard B. Colletti

  • Robert Baldassano

  • Frank Ruemmele

  • Anja Geldhof

  • Mark R. Molenda

  • Jay Popp

  • Kezhen L. Tang

  • James Markowitz

  • William A. Faubion

  • J. Fell

  • Benjamin D. Gold

  • Anne M. Griffiths

  • Jeffrey S. Hyams

  • Sibylle Koletzko

  • Subra Kugathasan

  • Gigi Veereman

Medical Centers

  • Hospital for Sick Children, Toronto, ON, Canada

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • Connecticut Children, Hartford, CT

  • Erasmus MC, Sophia Children's hospital, Rotterdam, Netherlands

  • Massachusetts General Hospital, Boston, MA

  • University of Vermont, Burlington, VT

  • Mayo Clinic, Rochester, Rochester, MN

  • KCE-Belgian Health Care Knowledge Centre, Belgium

  • Hopital Necker-Enfants Malades, Paris, France

  • Cohen Children's Medical Center, New Hyde Park, NY

  • Emory University School of Medicine, Atlanta, GA

  • Dr. von Haunersches Kinderspital, Ludwig-Maximilans-Universitat, Munich, Germany

  • Childrens Hospital of Philadelphia, Philadelphia, PA

  • Chelsea and Westminster Hospital, London, United Kingdom

  • Children's Center for Digestive Healthcare Pediatric Gastroenterology, United States

Locations

  • Canada

  • Italy

  • Netherlands

  • Germany

  • United Kingdom

  • United States

  • France

  • Belgium

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Inflammatory bowel disease

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab

Outcome

  • N/A

Study Design

  • observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved